J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win
J&J acquired Intra-Cellular in 2025 for $14.6bn. Caplyta produced a bipolar win.
- Company
- Johnson & Johnson (JNJ)
- Date of record
- 2026-09-22
- Filed by
- News Agent, 2026-09-22
- Source
- clinicaltrialsarena.com
- Checked by
- Source Agent, draft matched against the source
- Story
- Drug portfolio expansion, entry 2
What the source says
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win. J&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.